Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$19.47 -2.8%	$18.23	$16.10 ▼ $41.94	$2.52B	0.67	2.37 million shs	1.84 million shs
NAMS NewAmsterdam Pharma	$22.20 +1.0%	$19.35	$14.06 ▼ $27.29	$2.47B	-0.03	744,133 shs	951,534 shs
PHAT Phathom Pharmaceuticals	$7.95 -4.4%	$7.38	$2.21 ▼ $19.71	$580.85M	0.45	1.54 million shs	1.01 million shs
XENE Xenon Pharmaceuticals	$31.59 -1.7%	$31.50	$26.74 ▼ $46.00	$2.46B	1.1	643,430 shs	1.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-2.84%	+0.15%	+9.63%	+6.98%	-50.70%
NAMS NewAmsterdam Pharma	+1.00%	+3.06%	+21.98%	+35.86%	+18.02%
PHAT Phathom Pharmaceuticals	-4.45%	-13.40%	-27.06%	+97.27%	-34.35%
XENE Xenon Pharmaceuticals	-1.65%	-1.92%	-0.97%	-10.09%	-24.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.3291 of 5 stars	4.3	0.0	4.4	2.6	2.5	0.6
NAMS NewAmsterdam Pharma	3.6242 of 5 stars	4.4	2.0	0.0	2.0	5.0	0.0
PHAT Phathom Pharmaceuticals	4.3101 of 5 stars	4.5	4.0	0.0	2.2	5.0	0.6
XENE Xenon Pharmaceuticals	3.4743 of 5 stars	4.5	4.0	0.0	1.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.00	105.44% Upside
NAMS NewAmsterdam Pharma	2.89	Moderate Buy	$41.30	86.04% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	120.13% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	73.53% Upside

Current Analyst Ratings Breakdown

Latest PHAT, APLS, XENE, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/17/2025	NAMS NewAmsterdam Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$27.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	3.13	N/A	N/A	$1.84 per share	10.58
NAMS NewAmsterdam Pharma	$45.56M	54.71	N/A	N/A	$8.20 per share	2.71
PHAT Phathom Pharmaceuticals	$55.25M	10.05	N/A	N/A	($3.71) per share	-2.14
XENE Xenon Pharmaceuticals	$9.43M	257.04	N/A	N/A	$9.90 per share	3.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/14/2025 (Estimated)

Latest PHAT, APLS, XENE, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PHAT Phathom Pharmaceuticals	-$0.76	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	NAMS NewAmsterdam Pharma	-$0.52	N/A	N/A	N/A	$1.44 million	N/A
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
NAMS NewAmsterdam Pharma	89.89%
PHAT Phathom Pharmaceuticals	99.01%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
NAMS NewAmsterdam Pharma	20.84%
PHAT Phathom Pharmaceuticals	23.00%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

PHAT, APLS, XENE, and NAMS Headlines

Recent News About These Companies

CenterBook Partners LP Makes New $745,000 Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

July 18 at 11:37 AM | marketbeat.com

TimesSquare Capital Management LLC Has $25.01 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

July 14, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Brokerages

July 10, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages

July 10, 2025 | marketbeat.com

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

July 10, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Cross Below 200 Day Moving Average - Here's Why

July 5, 2025 | marketbeat.com

Xenon Appoints CEO Ian Mortimer as Interim CFO

July 3, 2025 | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Nasdaq

June 29, 2025 | nasdaq.com

Xenon Pharmaceuticals Joins Russell 3000® and 2000® Indexes

June 27, 2025 | tipranks.com

Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution

June 27, 2025 | quiverquant.comQ

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | financialpost.comF

Xenon Joins the Russell 3000® and Russell 2000® Indexes

June 27, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 26, 2025 | globenewswire.com

Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)

June 26, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Passes Below 50 Day Moving Average - What's Next?

June 25, 2025 | marketbeat.com

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

June 24, 2025 | globenewswire.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, APLS, XENE, and NAMS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$19.47 -0.57 (-2.84%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$19.97 +0.50 (+2.57%)

As of 07/18/2025 07:46 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$22.20 +0.22 (+1.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$22.20 +0.00 (+0.02%)

As of 07/18/2025 05:49 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Phathom Pharmaceuticals NASDAQ:PHAT

$7.95 -0.37 (-4.45%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.99 +0.04 (+0.55%)

As of 07/18/2025 07:55 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Xenon Pharmaceuticals NASDAQ:XENE

$31.59 -0.53 (-1.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$31.59 0.00 (0.00%)

As of 07/18/2025 04:39 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time